You are using a browser version with limited support for CSS.
“This could dramatically reduce the amount of time a patient must spend in the hospital and hopefully be a critical component to every bone marrow transplant procedure in the near future.” The clinical trial will take place in two FDA-approved medical centers in Israel: Schneider Children’s Hospital in Petach Tikvah and Hadassah Ein Kerem in Jerusalem.
By working overseas, Taiga believes it can reduce the cost of the clinical trial and have better access to patients afflicted with this rare genetic disorder.
Infants with SCID suffer from repeated life-threatening infections that usually lead to a diagnosis by the age of three to six months.
Left untreated, children continue to experience severe infections; this usually leads to death by 2 years of age.
Such statements are based on management’s current expectations and involve risks and uncertainties.